1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole → 2-Chloro-5-(1-methyl-1H-pyrazol-4-yl)phenyl 2,3,4-tri-O-acetyl-5-thio-beta-D-xylopyranoside
Reaktionsgleichung
[CH3:1][N:2]1[CH:6]=[C:5](B2OC(C)(C)C(C)(C)O2)[CH:4]=[N:3]1.[C:16]([O:19][C@@H:20]1[C@@H:34]([O:35][C:36](=[O:38])[CH3:37])[C@H:33]([O:39][C:40](=[O:42])[CH3:41])[CH2:32][S:31][C@H:21]1[O:22][C:23]1[CH:28]=[C:27](Br)[CH:26]=[CH:25][C:24]=1[Cl:30])(=[O:18])[CH3:17]>>[C:16]([O:19][C@@H:20]1[C@@H:34]([O:35][C:36](=[O:38])[CH3:37])[C@H:33]([O:39][C:40](=[O:42])[CH3:41])[CH2:32][S:31][C@H:21]1[O:22][C:23]1[CH:28]=[C:27]([C:5]2[CH:4]=[N:3][N:2]([CH3:1])[CH:6]=2)[CH:26]=[CH:25][C:24]=1[Cl:30])(=[O:18])[CH3:17]Komponenten
3
Versuchsvorschrift
By carrying out the operation analogously to example 87, starting from 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 5-bromo-2-chlorophenyl 2,3,4-tri-O-acetyl-5-thio-β-D-xylopyranoside obtained according to preparation X, the expected product is obtained and is reacted further without additional purification in order to obtain the nonacetylated xyloside.